All terms
Decentralized Clinical Trial
A trial that uses telehealth, home-based assessments, wearables, and direct-to-patient logistics to reduce or eliminate site visits.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026
Definition
A Decentralized Clinical Trial (DCT) executes some or all trial activities — consent, screening, assessments, drug or device delivery, data collection — outside traditional brick-and-mortar investigator sites. Common DCT components include eConsent, telehealth visits, home health visits, direct-to-patient shipping of investigational product, wearable and connected sensor data capture, and ePRO. FDA issued a draft DCT guidance in May 2023 and finalized it in September 2024. What the regulation says
FDA Guidance: 'Decentralized Clinical Trials for Drugs, Biological Products, and Devices' (September 2024). EMA, MHRA, and Health Canada have parallel DCT guidance documents.
What this means in practice
DCT components are now standard tools rather than the experimental exception. MedTech-specific DCT use cases include long-term wearable monitoring and remote device-data collection where home use is the actual indication. Common pitfalls
- •Treating DCT as a cost-cutting measure rather than a design choice that can either improve or harm data quality depending on execution.
- •Underestimating eConsent regulatory and human-factors validation requirements.
Primary references
3 sourcesLink health: 2 verified 1 bot-blocked· last checked 2026-05-09
FDA·1EMA / EC·1ICH·1
- 1
FDA — Decentralized Clinical Trials Guidance (2024)Bot-blockedFDAfda.gov
- 2
EMA — Recommendation Paper on Decentralised Elements in Clinical TrialsVerifiedEMA / EChealth.ec.europa.eu
- 3
ICH GuidelinesVerifiedICHich.org
Inline markers like [1] jump to the matching reference above.